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Abstract
The objective of the research was to optimize treatment of patients with ischemic heart disease (postinfarction cardiosclerosis)
and concomitant phenomenon of heart rate turbulence based on the study of heart rate turbulence and heart rate variability.
Materials and methods. The study included 100 patients with ischemic heart disease and postinfarction cardiosclerosis
complicated by cardiac rhythm disorder (ventricular ectopic beats). Patients were divided into 2 groups according to the type
of prophylaxis: Group I received bisoprolol; Group II received quercetin in addition to bisoprolol. A daily dose of bisoprolol
was 0.07 mg/kg body weight while a daily dose of quercetin was 1g for 7 days. The control of therapy effectiveness was
performed using Holter monitoring of heart rate turbulence and heart rate variability.
Results. Bisoprolol intake by patients with ischemic heart disease and concomitant heart rate turbulence led to significant
increase in the stress index as well as the decrease in the overall tension of body regulation, either parasympathetic
or sympathetic divisions of the autonomic nervous system and the vasomotor center. Drug intake did not lead to the
abnormal physiological correlation between the activity of the subcortical and peripheral components of the nervous systems.
While analyzing the changes in the indices of heart rate turbulence and heart rate variability, there was found, that during
combination treatment of patients with ischemic heart disease using bisoprolol and quercetin, positive changes appeared in
the regulatory parts of the body.
Conclusions. Combination treatment of post-myocardial infarction patients with bisoprolol and quercetin allows us: a) to
achieve complete reduction in ventricular ectopic activity in more than half of patients; b) to reduce the number of patients with
life-threatening ventricular ectopic beats significantly; c) to maintain the physiological value and the activity of the autonomic
nervous system as well as the vasomotor center of the body; d) to decrease the level of turbulence onset and maintain the
value of turbulence slope.
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Problem statement and analysis of the
recent research
Abnormal cardiac rhythms, either in the early or late postin-
farction periods, is not a rare phenomenon [1]. In many cases,
sudden cardiac death is the first but at the same time the fatal
manifestation of heart disease; therefore, the main direction
of many recent studies in cardiology is the search for new risk
markers and effective ways of sudden cardiac death prevention
[2-4]. Well-studied ectopic parameters such as quantity, gra-
dation and morphology of ventricular ectopies and variability
of QT interval duration being recorded by Holter monitoring
remain to be useful predictors of high risk when deciding the
necessity of cardioverter-defibrillator implantation or antiar-
rhythmic therapy [5]. Currently existing selection criteria for
primary prevention of cardiac death are not effective [1].The
study of the measurements on the electrocardiogram (ECG) is
closely connected with ventricular ectopy; the analysis of their
relationships with autonomic regulation provides the basis for
new methods of diagnostics and treatment of risk-stratified
markers of sudden cardiac death. When selecting an antiar-
rhythmic drug, a doctor should always consider the state of
the autonomic regulation of cardiac activity [6]. For instance,
reduced indices of heart rate variability (HRT) indicate im-
balance of autonomic regulation of cardiac rhythm alongside
with weakened activity of the parasympathetic part of the
autonomic nervous system resulting in decreased threshold
of developing ventricular disorders of cardiac rhythm of high
gradations [7].
The objective of the research was to optimize treatment
of patients with ischemic heart disease (IHD) (postinfarc-
tion cardiosclerosis) and concomitant heart rate turbulence
(HRT) based on the study of HRT and HRV using β1-selective
adrenoblocker (bisoprolol) and quercetin.
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1. Materials and methods
The study included 100 patients with IHD and postinfarction
cardiosclerosis complicated by cardiac rhythm disorder (ven-
tricular ectopic beats (VEBSs). Patients were divided into 2
groups according to the type of prophylaxis: Group I received
bisoprolol; Group II received quercetin in addition to bisopro-
lol. A daily dose of bisoprolol was 0.07 mg/kg body weight
while a daily dose of quercetin was 1g for 7 days.
The determination of HRT and HRV was performed us-
ing the Holter monitoring system “CardioSens 2008”, “Car-
dioSens+V3.0” and “CardioSens CS” (“Medica-Khai”, Khar-
kiv, Ukraine).
The spectral analysis of HRT, which is based on the con-
struction of spectra of cardiac cycle length, was used in the
research. The analysis of the power spectral density of the
fluctuations allowed us to quantify various frequency com-
ponents of cardiac rhythm as well as a correlation between
different components of cardiac rhythm, which represent the
activity of certain components of regulative mechanism. In
the world scientific literature, the corresponding spectral com-
ponents are known as high-frequency (HF), low-frequency
(LF) and very low-frequency (VLF). According to the data
of the spectral analysis the following indices were calculated:
a) the centralization index (CI) = (HF+LF)/VLF), and the
vago-sympathetic interaction index (LF/HF). The power of
the VLF zone allows evaluating the effects of neurohumoral
factors. The size and correlation between different waves of
cardiac rhythm of the LF and HF zones are identified by sym-
pathetic and parasympathetic balance and parasympathetic
regulation, respectively. In addition to the determination of
component amplitude, there were measured the index of total
power (TP) – the total power of the spectrum which represents
the total activity of autonomic influences on heart rate and
LF/HF ratio which indicates the balance between sympathetic
and parasympathetic influences. The stress index (SI) charac-
terizes the degree of predominance of the activity of central
mechanisms over autonomic ones. This index is calculated on
the basis of analyzing the graph of cardiac interval distribution
– variational pulsogram. The activation of the central contour
as well as the increase in the sympathetic regulation during
psychic and physical stress manifests itself as cardiac rhythm
stabilization, the decrease in cardiac interval amplitude. This
index is very sensitive to the increase in the sympathetic ac-
tivity [8]. The analysis of HRT was performed based on two
indices – turbulence onset (TO) and turbulence slope (TS).
TO is a value of sinus rhythm acceleration immediately after
VEBs and TS is the intensity of sinus rhythm deceleration,
which comes after its acceleration. TO is calculated as the
ratio of differences between both the sum of values of the
first two sinus RR intervals occurring immediately after VEBs
and the next two sinus RR intervals occurring before VEBs
to the sum of two sinus RR intervals to VEBs, expressed as a
percentage.
To calculate TO the following formula was used:
TO(%) = 100∗ (RR[1]+RR[2])− (RR[−3]+RR[−2])
RR[−3]+RR[−2] (1)
where RR-2 and RR-3 are the first and second sinus RR
intervals that precede the ectopic complex; RR1 and RR2
are the first and second sinus RR intervals, which follow im-
mediately after the compensatory pause. To determine TS
(mc/RR) the tilt of the RR interval changes was calculated us-
ing straight lines of regression for each 5 RR intervals among
the next 20 after the compensatory pause RR [1]+RR [5]),
RR [2]+RR [6]) ... RR [16]+RR [20]). The value TS is
defined as the maximum positive regression slope. The param-
eters of acceleration (TO≤-1.5) and deceleration (TS≥2.5)
of the sinus cycle which occur immediately after premature
ventricular contraction are normal. The parameters of acceler-
ation (TO<0.0 and TO≥-1.5) or deceleration (TST >0.5) and
(TS<2.5) are considered pathological. If the parameter of ac-
celeration (TO>0.0) or deceleration (TS<0.5) is significantly
less than normal leves the risk of fatal ventricular ectopy is
very high. The acceleration of sinus rhythm, followed by
short-lasting slowdown, is considered as the physiological
response to VEBs [9-12].
All data were processed using statistical software STATIS-
TICA 10. The arithmetic mean (M), its variance and average
error (m) were calculated for all parameters. To determine
the reliability of differences between research results the Stu-
dent’s t-test was used and, then, the probability of differences
between samples (p) was determined; confidence interval was
calculated using Student’s t distribution.
The values for which p<0.05 were considered statistically
significant.
2. Results
Table 1 presents changes in the prevalence of VEBs among
patients with IHD according to our observations. The group of
patients who underwent combination treatment with bisopro-
lol and quercetin included people with more severe condition
- 59.08% of patients had life-threatening premature ventricu-
lar contractions, in 11.11% of patients early VEBs (Class V
according to the Lown classification) were recorded. In the
group of patients who received bisoprolol only the proportion
of patients with life-threatening extrasystole was 49.95%. The
number of patients with Lown Class I ventricular extrasystole
was almost identical between the groups; there were more
patients with Lown Class II ventricular extrasystole in the
group of patients who received bisoprolol only; the relative
number of patients with Lown Class III ventricular extrasys-
tole was almost identical between the groups; there were no
patients with Lown Class IV ventricular extrasystole in the
group of patients who received bisoprolol + quercetin. On the
background of treatment in individuals receiving bisoprolol
only, in 11.11% of patients with ventricular extrasystole there
was complete reduction in clinic and symptoms of arrhythmia;
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the number of patients with life-threatening extrasystole in-
creased from 49.95% to 58.98%. The number of patients with
Lown Class II did not change while the number of patients
with Lown Class I reduced twofold. On the background of
quercetin inclusion, in 54.54% of patients complete reduc-
tion in ventricular extrasystole was achieved. The number
of patients with life-threatening extrasystole reduced from
59.08% to 31.8%. The number of patients with Lown Class
I reduced twofold; there were no patients with Lown Class
II ventricular extrasystole; the number of patients with Lown
Class I reduced from 40.9% to 22.72%.
Table 2 presents the comparative characteristics of changes
in the parameters of HRV and HRT secondary to bisoprolol
intake. In patients receiving bisoprolol, a significant reduction
in the duration of the QT interval throughout the day (p<0.01)
which reduced cardiac electric systole (p<0.01) was observed.
In the active period of the day, in patients receiving bisoprolol
the SI increased twofold (p<0.01). The value of the total
tension of HRV reduced significantly by 56.82% (p<0.01),
and it occurred owing to all components (p<0.01). The ab-
solute value of HRV spectra after treatment with bisoprolol
decreased. Thus, HF spectrum decreased by 56.73%; LF
spectrum decreased by 58.36%, VLF spectrum decreased by
34.25% (p<0.01). The relative activity of subcortical sym-
pathetic centers remained unchanged being within the range
of 2.8. The CI in the active period of the day in patients re-
ceiving bisoprolol increased by 17.72%. In the passive period
of the day, on the background of treatment the SI increased
by 58.72% which was a significant difference (p<0.01). The
value of TS was significantly lower after treatment - by 61.37%
(p<0.01). In this case, only the values of LF and VLF spectra
were significantly lower – by 51.44 and 39.96% (p<0.01),
respectively. The HF parameters reduced by 19.22%, how-
ever, this difference was not significant. In patients receiving
bisoprolol the relative activity of subcortical sympathetic cen-
ter increased by 18.11% while the CI increased by 74.23%.
On the background of treatment with bisoprolol only - the
parameter of TO increased significantly (p<0.01). Before
treatment it was within normal range, after treatment it was
low. TS decreased by 19.5% on the background of treatment,
however, it was not a significant decrease in this indicator.
The next step was to determine change in HRT on the
background of ccombination treatment with beta-blockers
(bisoprol) and quercetin. Combination therapy with bisoprolol
and quercetin led to insignificant reduction in the duration of
the QT interval (Table 3). In the active period of the day, the SI
decreased by 16.68%, which was not a significant difference.
The total tension of HRV reduced significantly - by 4.19%.
The analysis of the value of individual HRV spectra found that
HF spectrum increased by 35.03%, LF spectrum increased by
36.87% and the activity of the sympathetic nervous system
(VLF spectrum) decreased by 13.57%. The relative activity
of subcortical sympathetic center increased insignificantly by
14.0%. The CI increased insignificantly as well - by 6.1%.
In the passive period of the day, the SI decreased on the
background of combination treatment being lower in contrast
to that prior to treatment - by 14.89%. The value of the
total tension of body regulation was not significantly lower
compared to that before treatment and the difference was
3.19%.
After combination treatment with bisoprolol and quercetin,
the activity of the parasympathetic nervous system increased
by 11.13%; the activity of the vasomotor center reduced by
35.55%; the activity of the sympathetic nervous system did
not decrease significantly - by 2.84%. The relative activity of
subcortical sympathetic center decreased by 4.18%. The CI
decreased by 0.02% only. During treatment with bisoprolol
and quercetin, positive dynamics was observed in changing
the parameters of HRT. Thus, TO decreased by 21.98% and
TS decreased by 8.95%.
3. Discussion
Half of patients with IHD die suddenly due to life-treatening
arrhythmias, especially ventricular tachycardias and irreversible
ventricular fibrillation. There are primary and secondary pre-
vention of sudden cardiac death. The last is applied in patients
who were saved from sudden cardiac death. In case of co-
existence of pathology and frequent ventricular extresytole
of high gradation the appropriate antiarrhythmic therapy is
chosen. The drugs of choice are ß-blockers, especially if ad-
ditional indications are present, namely IHD, hypertension,
sinus arrhythmia. ß-blockers are the only group of drugs used
for non-surgical prevention of sudden cardiac death in pa-
tients with acute myocardial infarction. High efficiency of
these drugs is associated with antiarrhythmic and bradicardial
action [6]. On the basis of the study results, we can state that
namely bisoprolol is the drug, which can prevent the develop-
ment of life-threatening ventricular ectopies including sudden
cardiac death. Bisoprolol intake by patients with IHD and
concomitant HRT phenomenon leads to significant increase
in the SI as well as the decrease in the overall tension of body
regulation, either parasympathetic or sympathetic divisions of
the autonomic nervous system and the vasomotor center. Drug
intake did not lead to the abnormal physiological correlation
between the activity of the subcortical and peripheral compo-
nents of the nervous systems. Bisoprolol intake increases the
CI, especially in the passive period of the day. This drug does
not increase the value of TO in patients with IHD; the value
of TS reduces insignificantly being within physiologically
acceptable limits. While analyzing the changes in the indices
of HRT and HRV, we can state, that during combination treat-
ment of IHD with co-existent HRT phenomenon there were
no significant changes in the indices of HRT and HRV. The
inclusion of quercetin allowed us to maintain the physiolog-
ical value and the activity of the autonomic nervous system
as well as the vasomotor center of the body and to decrease
the level of TO and maintain the value of TS. Considering the
resulting dynamics, we can state that combination treatment
of patients with myocardial infarction using bisoprolol and
quercetin allows us to achieve complete reduction in ventric-
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Table 1. Prevalence of VEBs on the background of treatment (the Lown classification)
I II III IV V No arrhythmia
Bisoprolol before treatment 6 (33.3%) 3 (16.6%) 8 (44.4%) 1 (5.55%) 0 -
Bisoprolol after treatment 3 (16.6%) 3 (16.6%) 9 (50%) 1 (5.55%) 0 2 (11.11%)
Bisoprolol + quercetin be-
fore treatment
8 (36.36%) 1 (4.54%) 9 (40.9%) 0 (0%) 4 (18.18%) -
Bisoprolol + quercetin after
treatment
4 (18.18%) 0 (0%) 5 (22.72%) 1 (4.54%) 1 (4.54%) 12 (54.54%)
Table 2. Dynamics of changes in the parameters of HRV and HRT in patients with IHD on the background of bisoprolol
intake, (M±m)
QT, mc QTc,
mc
SI TP, mc2 HF, % LF, % HF, mc2 LF, mc2 VLF, mc2 LF/HF IC TO, % Ts,
mc/bit
Before
treatment
(day)
384.25
±4.77
405.95
±4.54
26.25
±2.8
5111.2
±910.88
30.08
±2.49
69.91
±2.49
834.9
±274.74
1504.0
±355.32
1677.25
±215.24
2.8 ±
0.34
8.35
±1.39
-2.35
±0.49
9.65
±1.78
After
treatment
(day)
369.61
±6.751
407.13
±6.15
52.52
±8.491
2904.26
±437.781
29.19
±2.36
70.81
±2.36
360.95
±175.591
626.39
±132.121
1102.74
±130.351
2.82
±0.23
9.83
±1.16
-1.14
±0.331
7.77
±1.63
Before
treatment
(night)
384.25
±4.77
405.95
±4.54
32.95
±3.66
6238.76
±981.04
30.33
±2.1
69.65
±2.1
1033.2
±219.54
2396.65
±529.29
2058.8
±263.86
2.65
±0.27
6.56
±1.01
-2.35
±0.49
9.65
±1.78
After
treatment
(night)
369.61
±6.751
407.13
±6.15
52.30
±10.211
3828.04
±486.351
29.48
±2.54
70.52
±2.54
827.30
±194.22
1163.56
±112.631
1235.56
±191.161
3.13
±0.44
11.43
±2.22
-1.14
±0.331
7.77
±1.63
Notes.
1 - difference p<0.01 before, during and after treatment
Table 3. Dynamics of changes in the parameters of HRV and HRT in patients with IHD on the background of quercetin intake,
(M±m)
QT, mc QTc,
mc
SI TP, mc2 HF, % LF, % HF, mc2 LF, mc2 VLF, mc2 LF/HF IC TO, % Ts,
mc/bit
Before
treatment
(day)
381.94
±11.57
412.29
±6.45
76.64
±4.89
4831.76
±1110.08
31.34
±2.66
68.64
±2.66
754.41
±346.93
1184.12
±370.28
1672.52
±265.87
2.57
±0.3
8.03
±1.28
-2.82
±0.7
9.95
±2.04
After
treatment
(day)
376.35
±4.81
419.35
±5.89
63.94
±16.8
4633.65
±1035.83
30.84
±3.86
69.17
±3.86
1018.17
±577.15
1620.65
±523.15
1445.17
±238.58
2.93
±0.39
8.52
±1.18
-3.44
±0.64
9.06
±1.32
Before
treatment
(night)
381.94
±11.57
412.29
±6.45
38.70
±12.23
5736.23
±1185.72
31.38
±2.26
68.61
±2.26
1171.94
±456.12
1882.70
±522.62
2046.76
±310.99
2.45
±0.23
7.41
±0.96
-2.82
±0.7
9.95
±2.04
After
treatment
(night)
376.35
±4.81
419.35
±5.89
32.94
±5.36
5553.23
±1159.73
34.22
±3.38
66.35
±3.41
1301.35
±660.24
1401.29
±292.41
1988.05
±315.73
2.35
±0.28
7.44
±2.22
-3.44
±1.04
9.06
±1.32
ular ectopic activity in more than half of patients as well as
to reduce the number of patients with life-threatening VEBs
significantly.
4. Conclusions
Combination treatment of post-myocardial infarction patients
using bisoprolol and quercetin allows us: a) to achieve com-
plete reduction in ventricular ectopic activity in more than
half of patients; b) to reduce the number of patients with
life-threatening VEBs significantly; c) to maintain the physio-
logical value and the activity of the autonomic nervous system
as well as the vasomotor center of the body; d) to decrease the
level of TO and maintain the value of TS.
5. Prospects for further research
The aforementioned data point to a promising combination
of a beta-blocker bisoprolol and quercetin when treating pa-
tients with impaired cardiac rhythm secondary to myocardial
ischemia.
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